Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Hypertension. 2016 Feb 29;67(5):927–933. doi: 10.1161/HYPERTENSIONAHA.115.07012

Figure 3.

Figure 3

Urinary excretion (per 24 hours) of renin (A), angiotensinogen (B) or albumin (C) before (control, CO) and after treatment with indol-3-carbinol (I3C), with or without concomitant exposure to losartan (LOS) or hydralazine (HYD). *P<0.05 versus CO, †P<0.05 versus I3C, and $P<0.05 versus I3C-LOS. Data are mean±SEM of n=4-5.